Redeye provides its first take on Camurus’ Q4 report 2025, published this morning. Buvidal had its third sequential sales decline and were significantly lower than we had projected due to a one-time repurchase of inventory of SEK93m. Brixadi was in line with a 10% Q/Q growth rate. The EBIT margin decreased to 26% (30% in Q4 2024 and 42% in Q3 2025). The numbers were also impacted by a currency headwind. Overall, the report falls short of our expectations, just like Q3 did.
LÄS MER
